Fig. 4
From: The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells
IL-6-secreting TNBC cells attract IL-6R-expressing/PGE2-secreting MSCs, in the syngeneic model. a Schematic representation of the assays performed. b The volume of syngeneic mammary tumors developed following injection of 1 × 106 cells of 4T1/shCtrl (black, n = 10), 4T1/shIris1 (red, n = 10), or 4T1/shIris2 (blue, n = 10) cells. The inset shows the expression of Iris in these cells. c The levels of circulating IL-6 (upper) or PGE2 (lower) as detected using ELISA in mice bearing 4T1/shCtrl, 4T1/shIris1, or 4T1/shIris2 tumors. d FACS analysis of the percentage of IL-6R−CD29−, IL-6R−CD29+, IL-6R+CD29−, or IL-6R−CD29+ cells within 4T1/shCtrl and 4T1/shIris1 tumors (upper), or 4T1/shCtrl and 4T1/shIris2 tumors (lower). e Fluorescence IHC staining of MDA231/shCtrl or MDA231/shIris1 tumor sections with CK5 (green), the MSC marker CD90 (red) and IL-6R (yellow). In 3`, 5`, and 9`, arrowheads denote cancer cells and arrows denote MSCs. Scale bars = 100 μm in 1–6 and 7–12 and 50 μm in 3`, 9`, 5`, and 11`